Innovative Care. Trusted Quality.
We exist to make life-saving specialty medicines accessible — reliably, affordably, with the clinical integrity Pakistan's patients deserve.
Science-driven. Patient-centred. Built to make life-saving medicines accessible across Pakistan.
Salventis Pharma aspires to be the definitive bridge between global pharmaceutical innovation and Pakistan's healthcare system — recognised by clinicians, institutions, and patients as the standard of excellence in specialty pharmaceutical distribution. By 2030, Salventis will have established itself as the partner of choice for international pharmaceutical principals seeking credible, compliant, and commercially capable representation in Pakistan.
Every product decision grounded in clinical evidence. Science-driven commercialisation — never compromising quality for commercial gain.
We measure success in patient outcomes — every therapy represents a life touched, a condition managed, a family supported.
Full DRAP compliance and international regulatory expertise are foundational — not optional. We navigate complex frameworks to ensure safe, reliable delivery.
Strategic alliances with reputable international manufacturers — bringing monoclonal antibodies and specialty diagnostics into the Pakistani market.
Cold-chain integrity, on-time delivery, and supply reliability are operational standards — not aspirations. We deliver what we promise.
Building lasting value for healthcare institutions, principal partners, distribution networks, and the patients whose lives depend on innovative therapies.
We bridge the gap between global pharmaceutical innovation and Pakistan's healthcare professionals — one life-saving medicine at a time.
Zillur Rahman Qureshi · Founder & CEO, Salventis PharmaSalventis Pharma (SMC-Private) Limited is an Islamabad-based pharmaceutical distribution and marketing company dedicated to bridging the gap between global therapeutic innovation and Pakistan's healthcare system.
We operate across four therapeutic areas — anti-infectives, oncology & bone health, urology and gastroenterology — with a pipeline in oncology and contrast media. Our brands are manufactured for us by licensed pharmaceutical partners in Pakistan.
From Islamabad to every hospital and clinic across Pakistan — our medicines are making a measurable difference in patient lives, one vial at a time.
We bring carbapenem antibiotics, bisphosphonates, and contrast agents to hospitals, ICUs, and oncology centres that need them most — at prices that enable institutional procurement.
Zolegen® and Pregolix® support oncologists, urologists and bone specialists — from skeletal protection in advanced cancer to oral androgen deprivation in prostate cancer.
Actively seeking international collaborations in oncology, radiology, and specialty therapeutics — including monoclonal antibodies — to expand Pakistan's access to cutting-edge pharmaceutical innovations.
From four therapeutic areas today to a broader specialty portfolio — here is our path forward.
Merovion® (meropenem 500 mg & 1 g) and Tigradox® (tigecycline 50 mg) for hospital and critical care.
● LiveZolegen®, Pregolix®, Tamstone-D®, Tamstone® and Acosky® for specialist care.
● LiveIohexol and gadobutrol contrast media, and nab-paclitaxel. Regulatory status to be confirmed.
◐ PipelineA cardiovascular specialty portfolio is in planning.
○ Planned"A firm believer in ethical, science-driven commercialisation — with a consistent focus on innovation, operational excellence, and long-term value creation."
Zillur Rahman Qureshi brings over 50 years of distinguished pharmaceutical leadership across multinational and leading local organisations in Pakistan and internationally. Holding an MBA in Marketing complemented by extensive executive training in strategic planning, portfolio management, and international business.
His executive career spans C-suite and board-level roles — including Managing Director, Chief Operating Officer, and Director of Marketing — with landmark contributions to Sanofi Aventis and Boehringer Mannheim, as well as leading pharmaceutical groups across Pakistan.
Seven prescription brands across four therapeutic areas. Select a product for its scientific and prescribing information.
Product information is intended for healthcare professionals in Pakistan. All products are prescription-only medicines.
Be part of a team changing healthcare access in Pakistan — one life-saving medicine at a time.
At Salventis Pharma, we are building Pakistan's most trusted specialty pharmaceutical distributor. We are looking for passionate, science-driven professionals who share our commitment to improving patient outcomes and bringing innovative therapies to healthcare professionals across the country.
Salventis Pharma is actively seeking collaborations with international and local pharmaceutical principals — particularly in oncology, radiology, and specialty therapeutics, including monoclonal antibodies and diagnostic imaging products.
Curated pharmaceutical and healthcare news relevant to our therapeutic areas. Click any article to read on the original source — updated regularly.
Breaking news on FDA approvals, clinical trial results, oncology advances, and global biopharma industry developments — daily updates.
AI-driven drug development, advanced therapeutics, and cardiometabolic medicines dominate 2026 pipelines. Oncology and precision medicine at the forefront.
New pharmacokinetic data on tigecycline and meropenem in ICU settings. Pakistan's AMR agenda highlights growing demand for reserve IV antibiotics.
Hospital procurement, distribution partnerships, HCP enquiries, or investment discussions — we're ready to help.